Investment Strategy
We maintain positions in both private and public companies, with a focus on opportunities where strategic involvement can accelerate returns.
We selectively take stakes in undervalued public companies — particularly those trading at a discount to their net tangible asset value — where we can:
- Add strategic value
- Introduce new investors or acquisition opportunities
- Influence or redirect corporate strategy
When warranted, we may seek to acquire and take companies private. In many cases, our involvement accelerates outcomes, either through direct action or by attracting third-party interest. This approach shortens our investment horizon while unlocking value.
Funding Access
We maintain close relationships with several sophisticated capital partners:
Family Office / Investment Banking Group
- Backing late-stage public companies with near-term funding needs
- Ticket size: $5M–$500M (typically $20M+)
- Target profile: NASDAQ/NYSE-listed, high-potential, controlled burn
- Sector-agnostic, with a preference for biotech
- No syndication required; not subject to private equity or hedge fund practices (e.g., markdowns or short-selling)
Private Equity Firm (AUM: £67B)
- Seeks companies with $10M+ EBITDA and growth potential
- Open to acquisition or strategic partnership
- Investment size: £50M–£500M
- Industry exclusions: oil, defense, alcohol
Ready to Explore Opportunities?
Let's discuss how we can help accelerate your company's growth and value.
Book a Demo